Citations

Clear

426 citation(s) found for "ST, Reza".

International validation of the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score in heart failure
Adamopoulos, Stamatis , Miliopoulos, Dimitrios , Piotrowicz, Ewa , Snoek, Johan A. , Panagopoulou, Niki , Niederseer, David , Mazaheri, Reza , Ma, Jing , Chen, Yundai , Popović, Dejana , Seferović, Petar , Girola, Davide, Metra, Marco , Rosano, Giuseppe , Piepoli, Massimo , Corrà, Ugo , Agostoni, Piergiuseppe , Metra, Marco , Nanas, Serafim , Corrà, Ugo , Coats, Andrew J.S. , Volterrani, Maurizio , Apostolo, Anna , Campodonico, Jeness , Salvioni, Elisabetta

Mayo Clinic

European Journal of Preventive Cardiology | June 8, 2023 | Volume: 30 | Issue: 13 | Pages: 1371-1379

10.1093/eurjpc/zwad191 | PMID 37288595 Get It

Abstract Aims Current European heart failure (HF) guidelines suggest the use of risk score: among them, the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score has demonstrated to be one of the most accurate. However, the risk scores are still poorly implemented in clinical practice, also due to the lack of strong evidence regarding their external validation in different populations. Thus, the current study was designed as an external validation test of the MECKI score in an international multicentre setting. Methods and results The study cohort consisted of patients diagnosed with HF with reduced ejection fraction (HFrEF) across international centres (not Italian), retrospectively recruited. Collected data included demographics, HF aetiology, laboratory testing, electrocardiogram (ECG), echocardiographic findings, and cardiopulmonary exercise testing (CPET) results as described in the original MECKI score publication. A total of 1042 patients across 8 international centres (7 European and 1 Asian) were included and followed up from 1998 till 2019. Patients were divided according to the calculated MECKI scores into three subgroups: (i) MECKI score <10%, (ii) 10–20%, and (iii) ≥ 20%. Survival analysis comparison among the three MECKI score subgroups showed a worse prognosis in patients with higher MECKI score value: median event-free survival times were 4396 days for MECKI score <10%, 3457 days for 10–20%, and 1022 days for ≥20% (P < 0.0001). Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) were like those reported in the original internal validation studies. Conclusion In patients diagnosed with HFrEF, the power of the MECKI score was confirmed in terms of prognosis and risk stratification, supporting its implementation as advised by the HF guidelines.
Tolerability of lutetium-177–PSMA-617 in men with prostate cancer and baseline cytopenia.
Abdelrazek, Ahmad , Mahmoud, Ahmed , Bach, Corrie R. , Orme, Jacob J. , Rodrigo, Rodrigues Pessoa, Kwon, Eugene D., Mahmoud, Ahmed M , Johnson, Geoffrey B. , Johnson, Derek R. , Nabavizadeh, Reza , Thorpe, Matthew , Kendi, A. Tuba , Childs, Daniel S.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e17057-e17057

10.1200/jco.2023.41.16_suppl.e17057 Get It

e17057 Background: Results from the VISION trial (NCT03511664) led to the approval of lutetium-177 (177Lu)–PSMA-617 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This trial excluded patients with baseline cytopenias, thus safety in this frequently encountered patient population is unknown. We aimed to use real-world data to describe the tolerability of radioligand therapy in those with poorer bone marrow reserve. Methods: We retrospectively reviewed the records of all patients, who received a first dose of 177Lu–PSMA-617 at Mayo Clinic in the interval of April 26, 2022, to December 1, 2022. Patients were categorized as having poor marrow reserve on the basis of pre-treatment hematologic parameters, including: (1) an anemia cohort with hemoglobin (Hg) less than 9 g/dL, (2) a thrombocytopenia cohort with platelets (Plt) less than 100 x 109/L, (3) a leukopenia cohort with white blood cell count (WBC) less than 2.5 x 109/L, and (4) a multiple cytopenia cohort. These were exclusionary parameters from the VISION trial. Longitudinal laboratory data and clinical outcomes were collected and analyzed using descriptive statistics. Results: At data cutoff, 185 patients had received one or more doses of 177Lu, including 26 (14%) with at least one baseline cytopenia prior to their first cycle of treatment. In total, there were 19 (73%) patients with anemia, 3 (12%) with thrombocytopenia, 2 (8%) with leukopenia, and 2 (8%) with multiple cytopenias at baseline. The median number of cycles received thus far is 3, including 14 (54%) who are still receiving therapy and 12 (46%) who have permanently discontinued treatment. Median longitudinal changes in blood counts for the anemia cohort are presented in Table 1. Reasons for treatment discontinuation include: toxicity (n = 2), disease progression (n = 5), death (n = 4), or other (n = 1). Dose reductions or treatment delays for worsening myelosuppression were utilized in 3 (12%) and 5 (19%) patients, respectively. Transfusions of packed red blood cells or platelets were required for 16 (62%) patients. A total of 6 (23%) received care in the emergency department or were hospitalized. Conclusions: Treatment discontinuation for toxicity was rare among men with mCRPC and baseline cytopenias, while receiving 177Lu; however, these patients have an overall poor prognosis. [Table: see text]
Unexpected discovery of a bicuspid pulmonary valve on 3D transoesophageal echocardiography
Lee, Hong S, Apolinario, Michael , Farina, Juan M. , Arsanjani, Reza , Apolinario, Michael A, Arsanjani, Reza , Farina, Juan M , Majdalany, David S

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | June 2, 2023 | Volume: 24 | Issue: 9 | Pages: e271-e271

10.1093/ehjci/jead127 | PMID 37267328 Get It

Gastroprotective effect of sumatriptan against indomethacin‐, stress‐ and ethanol‐induced gastric damage in male rats: Possible modulatory role of 5‐hydroxytryptamine 1B/1D receptors and pro‐inflammatory cytokines
Ostovaneh, A. , Eslami, Faezeh , Dejban, Pegah, Shafaroodi, Hamed , Shahsavarhaghighi, Shirin, Dehpour, Ahmad Reza , Shafaroodi, Hamed , Dehpour, Ahmad Reza , Rahimi, Nastaran , Abbasi, Ata

Mayo Clinic

Basic & Clinical Pharmacology & Toxicology | May 30, 2023 | Volume: 133 | Issue: 2 | Pages: 156-167

10.1111/bcpt.13905 | PMID 37248787 Get It

AbstractThe current study was aimed to investigate the beneficial effect of sumatriptan, a 5‐hydroxytryptamine 1B/1D (5HT1B/1D) receptor agonist, on gastric ulcer in rats via stimulating 5HT1B/1D receptors and suppressing pro‐inflammatory cytokines. Rats were allocated into three models of gastric ulcer: indomethacin (30 mg/kg, PO), water immersion restraint stress (WRS) and ethanol (5 ml/kg PO). Animals were administered with sumatriptan (0.01, 0.1, 0.3 and 1 mg/kg, i.p) 30 min before gastric ulcer induction. GR‐127935 (0.01 mg/kg, i.p, a selective 5HT1B/1D antagonist) was administered 30 min before sumatriptan (0.1 mg/kg) injection. Macroscopic assessments (J‐score), ELISA analysis of tumour necrosis factor‐alpha (TNF‐α) and interleukin‐1beta (IL‐1β) and histopathological changes were performed on the rat's stomach tissues. Gastric ulcer induction in three models caused an increase in J‐score, TNF‐α, IL‐1β and microscopic features. Sumatriptan (0.1 mg/kg) significantly improved gastric injury induced by indomethacin, WRS and ethanol through the reduction in the J‐score, TNF‐α, IL‐1β and microscopic lesions. Concurrent administration of GR‐127935 (0.01 mg/kg) with sumatriptan (0.1 mg/kg) reversed the gastroprotective effect of sumatriptan in three models. Sumatriptan possessed gastroprotective effects on indomethacin‐, WRS‐ and ethanol‐induced gastric damage in rats via the possible involvement of the 5HT1B/1D receptors.
Impact of statins based on high-risk plaque features on coronary plaque progression in mild stenosis lesions: results from the PARADIGM study
Sung, Ji Min , Lee, Byoung Kwon , Lin, Fay Y. , Hadamitzky, Martin , Kim, Yong‐Jin , Andreini, Daniele , Pontone, Gianluca , Chun, Eun Ju , Cademartiri, Filippo , Maffei, Erica , Marques, Hugo , Leipsic, Jonathon , Choi, Jung Hyun , Virmani, Renu , Samady, Habib , Chinnaiyan, Kavitha M. , Stone, Peter H. , Berman, Daniel S. , Shaw, Leslee J. , Min, James K. , Chang, Hyuk‐Jae , Cademartiri, Filippo , Virmani, Renu , Chang, Hyuk-Jae , Park, Hyung‐Bok , Arsanjani, Reza , Heo, Ran , Conte, Edoardo , Budoff, Matthew J. , Gottlieb, Ilan , Gonçalves, Pedro de Araújo , Lee, Sang‐Eun , Shin, Sanghoon , Narula, Jagat , Bax, Jeroen J.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | May 26, 2023 | Volume: 24 | Issue: 11 | Pages: 1536-1543

10.1093/ehjci/jead110 | PMID 37232393 Get It

Abstract Aims To investigate the impact of statins on plaque progression according to high-risk coronary atherosclerotic plaque (HRP) features and to identify predictive factors for rapid plaque progression in mild coronary artery disease (CAD) using serial coronary computed tomography angiography (CCTA). Methods and results We analyzed mild stenosis (25–49%) CAD, totaling 1432 lesions from 613 patients (mean age, 62.2 years, 63.9% male) and who underwent serial CCTA at a ≥2 year inter-scan interval using the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (NCT02803411) registry. The median inter-scan period was 3.5 ± 1.4 years; plaques were quantitatively assessed for annualized percent atheroma volume (PAV) and compositional plaque volume changes according to HRP features, and the rapid plaque progression was defined by the ≥90th percentile annual PAV. In mild stenotic lesions with ≥2 HRPs, statin therapy showed a 37% reduction in annual PAV (0.97 ± 2.02 vs. 1.55 ± 2.22, P = 0.038) with decreased necrotic core volume and increased dense calcium volume compared to non-statin recipient mild lesions. The key factors for rapid plaque progression were ≥2 HRPs [hazard ratio (HR), 1.89; 95% confidence interval (CI), 1.02–3.49; P = 0.042], current smoking (HR, 1.69; 95% CI 1.09–2.57; P = 0.017), and diabetes (HR, 1.55; 95% CI, 1.07–2.22; P = 0.020). Conclusion In mild CAD, statin treatment reduced plaque progression, particularly in lesions with a higher number of HRP features, which was also a strong predictor of rapid plaque progression. Therefore, aggressive statin therapy might be needed even in mild CAD with higher HRPs. Clinical trial registration ClinicalTrials.gov NCT02803411
(157) Advanced Practice Providers Deliver Equivalent Outcomes with CCH Injection for Peyronie’s Disease
Carlson, Stephanie K., Tentis, E, Nelson, Kevin M., Alom, Mulham , Tobias, Karen Swalec, Matthew, Ziegelmann, Roshandel, Reza , Helo, Sevann , Tobias, K

Mayo Clinic

The Journal of Sexual Medicine | May 22, 2023 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/jsxmed/qdad060.152 Get It

Abstract Introduction Independently performed procedures by well-trained advanced practice providers (APP) facilitate access to specialized care. We sought to compare outcomes between physicians and APPs with intralesional collagenase clostridium histolyticum (CCH). Objective Compare outcomes of CCH injections based on injection provider. Outcomes included curvature improvement and adverse events. Methods Men receiving CCH between 2014-2021 at our institution by four physicians and four APPs were included in an IRB-approved database. CCH was delivered as a series of 8 injections per protocol. Patient demographics, procedural-related adverse events, and curvature changes were recorded. The “APP-ratio” is defined as percentage of total injections administered by an APP per patient. Results After excluding patients who did not complete the entire CCH course or return for final assessment, 150/406 patients were analyzed. Mean baseline penile curvature was 66.2° (SD 23). Mean absolute and percent improvements in curvature were 21.7° (SD 18) and 33% (SD 27). The mean APP ratio was 69%, and 133 patients (89%) had at least 25% of their injections performed by an APP. There was no significant difference (p=0.65, p=0.39) in absolute or relative curvature improvement based on the APP-ratio [Figure 1]. There was also no difference in adverse events (pain, swelling, and hematoma). Conclusions In our high-volume CCH practice, APPs achieve the same outcomes and safety compared to physicians. Greater training efforts expand access to care for patients with PD. Disclosure No
A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma
An, Zesheng , Hsu, Michelle A. , Gicobi, Joanina K. , Xu, Tianxiao , Harrington, Susan M. , Pavelko, Kevin D. , Hirdler, Jacob B. , Lohse, Christine M. , Nabavizadeh, Reza , Pessoa, Rodrigo Rodrigues , Sharma, Vidit , Thompson, R. Houston, Leibovich, Bradley C. , Pavelko, Kevin D , Pessoa, Rodrigo R, Leibovich, Bradley C , Dong, Haidong , Lucien, Fabrice , Zhang, Henan , Dong, Haidong , Lucien, Fabrice

Mayo Clinic

The Journal of Immunology | May 10, 2023 | Volume: 210 | Issue: 12 | Pages: 2029-2037

10.4049/jimmunol.2200933 | PMID 37163328 Get It

Abstract The intrinsic and acquired resistance to PD-1/PD-L1 immune checkpoint blockade is an important challenge for patients and clinicians because no reliable tool has been developed to predict individualized response to immunotherapy. In this study, we demonstrate the translational relevance of an ex vivo functional assay that measures the tumor cell killing ability of patient-derived CD8 T and NK cells (referred to as “cytotoxic lymphocytes,” or CLs) isolated from the peripheral blood of patients with renal cell carcinoma. Patient-derived PBMCs were isolated before and after nephrectomy from patients with renal cell carcinoma. We compared the efficacy of U.S. Food and Drug Administration (FDA)-approved PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, atezolizumab) and a newly developed PD-L1 inhibitor (H1A Ab) in eliciting cytotoxic function. CL activity was improved at 3 mo after radical nephrectomy compared with baseline, and it was associated with higher circulating levels of tumor-reactive effector CD8 T cells (CD11ahighCX3CR1+GZMB+). Treatment of PBMCs with FDA-approved PD-1/PD-L1 inhibitors enhanced tumor cell killing activity of CLs, but a differential response was observed at the individual-patient level. H1A demonstrated superior efficacy in promoting CL activity compared with FDA-approved PD-1/PD-L1 inhibitors. PBMC immunophenotyping by mass cytometry revealed enrichment of effector CD8 T and NK cells in H1A-treated PBMCs and immunosuppressive regulatory T cells in atezolizumab-treated samples. Our study lays the ground for future investigation of the therapeutic value of H1A as a next-generation immune checkpoint inhibitor and the potential of measuring CTL activity in PBMCs as a tool to predict individual response to immune checkpoint inhibitors in patients with advanced renal cell carcinoma.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Altman, Jessica K. , Bixby, Dale L. , Fathi, Amir T. , Foran, James M. , Gojo, Ivana , Hall, Aric C. , Maness, Lori J., Mangan, James K. , Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey , Ali, Moaath K. Mustafa , Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Percival, Mary-Elizabeth, Perl, Alexander E. , Rao, Dinesh S. , Shallis, Rory M. , Shami, Paul J. , Stein, Eytan M. , Stone, Richard M. , Sweet, Kendra , Uy, Geoffrey L. , Vachhani, Pankit , Cassara, Carly J., Freedman-Cass, Deborah A., Stehman, Katie, Uy, Geoffrey , Pollyea, Daniel Aaron , Jonas, Brian A. , Kishtagari, Ashwin , Lancet, Jeffrey E. , Mims, Alice S , Przespolewski, Amanda , Ravandi, Farhad , Thota, Swapna

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2023 | Volume: 21 | Issue: 5 | Pages: 503-513

10.6004/jnccn.2023.0025 | PMID 37156478 Get It

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.
The impact of moderate aortic stenosis in acute myocardial infarction: A multicenter retrospective study
Abraham, Bishoy , Fath, Ayman R. , Abdou, Merna , Elbanna, Mostafa , Suppah, Mustafa, Sleem, Mohamed, Eldaly, Abdullah S. , Aly, Mohamed , Agasthi, Pradyumna , Fortuin, David, Sabbagh, Abdallah El , Holmes, David R. , Fath, Ayman, Eldaly, Abdullah , El Sabbagh, Abdallah , Holmes, David R , Brilakis, Emmanouil S , Megaly, Michael S. , Farina, Juan M. , Aly, Mohamed, Chao, Chieh‐Ju , Alsidawi, Said , Alkhouli, Mohamad , Brilakis, Emmanouil S. , Arsanjani, Reza

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 5, 2023 | Volume: 102 | Issue: 1 | Pages: 159-165

10.1002/ccd.30676 | PMID 37146200 Get It

AbstractBackgroundAortic stenosis (AS) is associated with myocardial ischemia through different mechanisms and may impair coronary arterial flow. However, data on the impact of moderate AS in patients with acute myocardial infarction (MI) is limited.AimsThis study aimed to investigate the impact of moderate AS in patients presenting with acute myocardial infarction (MI).MethodsWe conducted a retrospective analysis of all patients who presented with acute MI to all Mayo Clinic hospitals, using the Enterprise Mayo PCI Database from 2005 to 2016. Patients were stratified into two groups: moderate AS and mild/no AS. The primary outcome was all cause mortality.ResultsThe moderate AS group included 183 (13.3%) patients, and the mild/no AS group included 1190 (86.7%) patients. During hospitalization, there was no difference between both groups in mortality. Patients with moderate AS had higher in‐hospital congestive heart failure (CHF) (8.2% vs. 4.4%, p = 0.025) compared with mild/no AS patients. At 1‐year follow‐up, patients with moderate AS had higher mortality (23.9% vs. 8.1%, p < 0.001) and higher CHF hospitalization (8.3% vs. 3.7%, p = 0.028). In multivariate analysis, moderate AS was associated with higher mortality at 1‐year (odds ratio 2.4, 95% confidence interval [1.4–4.1], p = 0.002). In subgroup analyses, moderate AS increased all‐cause mortality in STEMI and NSTEMI patients.ConclusionThe presence of moderate AS in acute MI patients was associated with worse clinical outcomes during hospitalization and at 1‐year follow‐up. These unfavorable outcomes highlight the need for a close follow‐up of these patients and for timely therapeutic strategies to best manage these coexisting conditions.
Estrogen Metabolites Regulate Airway Contractility by Modulating Airway Smooth Muscle Intracellular Calcium
Balraj, Premanand , Kumar, Ajay , Reza, M.I., Roos, B., Pabelick, C.M., Venkatachalem, S., Ambhore, Nilesh Sudhakar , Pabelick, C.M., Prakash, Y. S.

Mayo Clinic

A70. RELAX ALREADY! MECHANISTIC INSIGHTS INTO AIRWAY SMOOTH MUSCLE BIOLOGY | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2332-A2332

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2332 Get It